Investigational drug · Phase 3
DLBS2411
Also called: Redacid
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Functional Dyspepsia.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "DLBS2411"
First trial start
2022
Dec 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DLBS2411", any sponsor or status.
Conditions studied
As listed on its trial records.
- Functional Dyspepsia
Largest trials
Live from ClinicalTrials.gov: studies naming "DLBS2411" as an intervention, largest first.
- DLBS2411 Treatment For Functional DyspepsiaPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT05248802 · 106 participants · Start Dec 9, 2022 · Primary completion Oct 1, 2025
Drug: Placebo caplet of DLBS2411; DLBS2411 · For: Functional Dyspepsia
Sites: Semarang, Indonesia; Sukoharjo, Indonesia; Surakarta, Indonesia · 8 sites in all
Dexa Medica GroupIndustry
NCT01573403 · 54 participants · Start Apr 2012 · Primary completion Dec 2012
Drug: DLBS2411; DLBS2411 and 1 more · For: Gastric pH Regulation in Healthy Volunteers
Sites: Jakarta Center, Indonesia
- Efficacy and Safety of DLBS2411 in the Management of GERDPivotal-lookingTerminated
Dexa Medica GroupIndustry
NCT03367195 · 32 participants · Start Aug 16, 2018 · Primary completion May 4, 2020
Drug: Omeprazole; DLBS2411 and 2 more · For: Gastroesophageal Reflux Disease (GERD)
Sites: Bandung, Indonesia; Jakarta, Indonesia; Semarang, Indonesia · 5 sites in all
- DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic UlcersPivotal-lookingTerminated
Dexa Medica GroupIndustry
NCT02262169 · 32 participants · Start Oct 2014 · Primary completion Feb 2019
Drug: Omeprazole; Placebo caplet of DLBS2411 and 2 more · For: Non-Bleeding Peptic Ulcers
Sites: Denpasar, Indonesia
Newest research
PubMed records naming it or its code names, newest first.
- Gastroprotective Effect of DLBS2411 Bioactive Fraction from Cinnamomum burmannii Against Ethanol-Induced Gastric Damage in Rats.
Tjandrawinata RR, Nailufar F · J Exp Pharmacol 2020
- Hydrogen potassium adenosine triphosphatase activity inhibition and downregulation of its expression by bioactive fraction DLBS2411 from Cinnamomum burmannii in gastric parietal cells.
Tjandrawinata RR, Nailufar F, Arifin PF · Int J Gen Med 2013
Also in development for Functional Dyspepsia
- AcotiamideItopride HydrochloridePhase 32 trials
Getz Pharma · Postprandial Distress Syndrome, Functional Dyspepsia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.